MDRNA, Inc. Announces Research Study With Pfizer
News Apr 06, 2010
MDRNA, Inc. has announced a study effort with Pfizer. The relationship will focus on the evaluation of MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi).
Additional details of the collaboration were not disclosed. This marks MDRNA's fourth early collaborative effort announced with a major pharmaceutical company in the past nine months.
MDRNA will be responsible for formulating Pfizer's oligonucleotides in DiLA2 formulations for in vivo preclinical evaluation to be performed at Pfizer. Additionally, MDRNA's research team will design and synthesize UsiRNAs directed against targets specified by Pfizer.
"We are extremely pleased to be working with Pfizer, a world leader in the pharmaceutical industry," said Michael French, President and CEO of MDRNA. "As Pfizer has made a commitment to the research and development of RNAi therapeutics, this is a significant opportunity for MDRNA to again demonstrate the broad capabilities of its world-class research team and proprietary drug discovery engine for RNAi-based therapeutics."
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE